October 22, 2020 -- Amyris and the Infectious Disease Research Institute (IDRI) have announced that they will collaborate on the development of a new RNA vaccine platform, including a COVID-19 candidate.
The partnership will integrate IDRI's RNA vaccine platform, which includes its nanostructured lipid carrier (NLC) technology, with Amyris's semi-synthetic squalene (squalene is a natural organic compound taken from shark liver oil).
Under terms of the agreement, Amyris will co-own intellectual property developed to create a COVID-19 vaccine, any rights to any combination of IDRI materials and Amyris squalene, the preclinical and phase I clinical trial data, and the clinical study report, it said.
The project is expected to conclude in the first half of 2022, according to the firm.
Copyright © 2020 scienceboard.net